denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: Cleveland Clinic and The Aplastic Anemia and MDS International Foundation
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Diseases, Therapies
Hematology Disease Topics & Pathways:
Research, Diseases, Therapies
Friday, December 8, 2023: 7:00 AM-10:00 AM
Room 6CF
(San Diego Convention Center)
Chair:
Sudipto Mukherjee, MD, PhD, MPH, Cleveland Clinic
Disclosures:
Mukherjee: Bristol-Myers Squibb Co.: Honoraria, Other: Advisor or review panel participant; Celgene Corporation: Consultancy, Other: Advisor or review panel participant, Research Funding; Eusa Pharma: Consultancy, Other: Advisor or review panel participant; Teaching and Speaking; Novartis: Consultancy, Other: Advisor or review panel participant; Jazz Pharmaceuticals: Other: Research: Principal Investigator for Investigator Initiated Trials (The institution gets the funding); Abbvie Pharmaceuticals: Other: Advisor or review panel participant; Blueprint Medicines: Other: Advisor or review panel participant; McGraw Hill: Honoraria, Other: Editor of Hematology Oncology Board Review (ongoing); Aplastic Anemia and MDS International Foundation: Honoraria, Other: Activity Director of ASH Friday Satellite Symposium annually.
Speakers:
Abhay Singh, MD, MPH, Cleveland Clinic
,
Austin Kulasekararaj, MD, MBBS, FRCPath, MRCP, King's College Hospital
,
Esther Natalie Oliva, MD, Grande Ospedale Metropolitano Bianchi Melacrino Morelli
,
Marco Davila, MD, PhD, Roswell Park Comprehensive Cancer Center
,
Kristen Marie Pettit, MD, University of Michigan
and
Uma M. Borate, MD, The Ohio State University
Disclosures:
Singh: Rigel: Other: Advisor or review panel participant. Kulasekararaj: BioCryst: Consultancy; Samsung: Consultancy; Alexion, AstraZeneca Rare Disease: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; F. Hoffmann-La Roche Ltd: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene/BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Akari Therapeutics: Consultancy; Achillion: Consultancy. Oliva: Grande Ospedale Metropolitano BMM: Current Employment; Daiichi: Consultancy, Honoraria; Ryvu: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Alexion: Consultancy, Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Amgen: Honoraria, Speakers Bureau; Sobi: Honoraria, Speakers Bureau; Servier: Patents & Royalties; Bristol Myers Squibb: Consultancy, Honoraria, Speakers Bureau. Davila: Precision Biosciences: Other: Ownership interest (stock, stock options in a publicly owned company); Legend Biotech: Consultancy; Kite Pharma Inc.: Other: Teaching and Speaking; Caribou Biosciences: Consultancy; Capstan: Other: Advisor or review panel participant; CRISPR (CRSP): Patents & Royalties: Intellectual property rights (Royalties or patent sales); Bellicum Pharmaceuticals, Inc.: Other: Advisor or review panel participant; Ownership interest (stock, stock options in a publicly owned company); Adicet: Consultancy; Atara Biotherapeutics: Consultancy; Synthekine: Consultancy; Syncopation Life Sciences: Consultancy; Adaptive Biotechnologies: Other: Ownership interest (stock, stock options in a publicly owned company). Pettit: Protagonist Therapeutics, Inc.: Consultancy, Research Funding; Merck: Research Funding, Speakers Bureau; AbbVie: Consultancy, Research Funding. Borate: Blueprint: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Agios: Membership on an entity's Board of Directors or advisory committees; Genentech: Membership on an entity's Board of Directors or advisory committees; Pfizer: Other: Research; Jazz: Other: Research; Abbvie: Membership on an entity's Board of Directors or advisory committees, Other: Research; Incyte: Other; Astellas: Membership on an entity's Board of Directors or advisory committees; Kura: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; RUNX1 Foundation: Honoraria; Takeda: Membership on an entity's Board of Directors or advisory committees.
On Demand program will be available here mid-January.
The Cleveland Clinic Center for Continuing Medical Education, Cleveland Clinic Taussig Cancer Institute, and the Aplastic Anemia and MDS International Foundation, Inc. (AAMDSIF) join together to present a live and enduring continuing medical education activity focusing on clonal hematopoiesis, low and high risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), aplastic anemia and paroxysmal nocturnal hemoglobinuria (AA & PNH) and cellular therapies for AML.
This CME-certified activity will provide an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with myeloid malignancies including AA, PNH, MDS, AML, MPN and related myeloid malignancies. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.
See more of: Friday Satellite Symposia